Abstract | OBJECTIVE: METHODS: RESULTS: 13 patients (13.0%) were diagnosed with deep venous thrombosis (DVT) in Group A, 7 of them were symptomatic, 3 were suspected of pulmonary embolism, and 2 suffered from cardio-cerebrovascular event. In Group B, 10 patients (7.1%) had DVT, 4 of them were symptomatic; suspicious pulmonary embolism and cardio-cerebrovascular event were diagnosed in 3 and 8 patients respectively. There were no statistic significances between the two groups in all these aspects. The quantity of bleeding, decrease of hemoglobin, hematoma rate, and infection rate of Group A were (693.4 +/- 480.1) ml, (32.9 +/- 18.0) g/L, 1%, and 0% respectively, all not significantly different from those of Group B (648.9 +/- 521.1) ml, (36.4 +/- 21.9) g/L, 2.1%, and 1.4% respectively, all P > 0.05. CONCLUSION:
Aspirin is as effective as LMWH in venous thromboembolism prophylaxis after total joint arthroplasty. In addition, aspirin is cheap, administered orally, well tolerated, without necessity for surveillance, and with good compliance and potential of prevention of cardio-cerebrovascular events.
|
Authors | Hua Tian, Fei Song, Ke Zhang, Yan Liu |
Journal | Zhonghua yi xue za zhi
(Zhonghua Yi Xue Za Zhi)
Vol. 87
Issue 47
Pg. 3349-52
(Dec 18 2007)
ISSN: 0376-2491 [Print] China |
PMID | 18478950
(Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Anticoagulants
- Heparin, Low-Molecular-Weight
- Tablets, Enteric-Coated
- Aspirin
|
Topics |
- Aged
- Anti-Inflammatory Agents, Non-Steroidal
(adverse effects, therapeutic use)
- Anticoagulants
(adverse effects, therapeutic use)
- Arthroplasty, Replacement, Hip
(adverse effects)
- Arthroplasty, Replacement, Knee
(adverse effects)
- Aspirin
(adverse effects, therapeutic use)
- Female
- Heparin, Low-Molecular-Weight
(adverse effects, therapeutic use)
- Humans
- Male
- Middle Aged
- Pulmonary Embolism
(chemically induced)
- Tablets, Enteric-Coated
- Treatment Outcome
- Venous Thromboembolism
(etiology, prevention & control)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|